Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Carmichael

Showing results (201-210 of 214) with videos related to

Pageof 22
Sort By:
JCI Insight|May 18, 2018
Elevated hepatic expression of H19 long noncoding RNA contributes to diabetic hyperglycemiaNa Zhang, Tingting Geng, Zhangsheng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.
Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2008
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Asna Amin, Linda C Benavides, Jarrod P Holmes, et al.
Current Biology : CB|February 25, 2023
Emergence, continuity, and evolution of Yersinia pestis throughout medieval and early modern DenmarkKatherine Eaton, Ravneet K Sidhu, Jennifer Klunk, et al.
Tissue Antigens|June 16, 2006
Association of canine hypothyroidism with a common major histocompatibility complex DLA class II alleleL J Kennedy, S Quarmby, G M Happ, et al.
Vaccine|September 23, 2010
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptideJeremy D Gates, Guy T Clifton, Linda C Benavides, et al.
Nucleic Acids Research|November 17, 2014
The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cellsYuan Gao, Fuju Wu, Jichun Zhou, et al.
The Journal of Clinical Investigation|October 3, 2022
TET3 epigenetically controls feeding and stress response behaviors via AGRP neuronsDi Xie, Bernardo Stutz, Feng Li, et al.
Pageof 22

Showing results (201-210 of 214) with videos related to

Sort By:
Pageof 22
JCI Insight|May 18, 2018
Elevated hepatic expression of H19 long noncoding RNA contributes to diabetic hyperglycemiaNa Zhang, Tingting Geng, Zhangsheng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.
Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2008
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Asna Amin, Linda C Benavides, Jarrod P Holmes, et al.
Current Biology : CB|February 25, 2023
Emergence, continuity, and evolution of Yersinia pestis throughout medieval and early modern DenmarkKatherine Eaton, Ravneet K Sidhu, Jennifer Klunk, et al.
Tissue Antigens|June 16, 2006
Association of canine hypothyroidism with a common major histocompatibility complex DLA class II alleleL J Kennedy, S Quarmby, G M Happ, et al.
Vaccine|September 23, 2010
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptideJeremy D Gates, Guy T Clifton, Linda C Benavides, et al.
Nucleic Acids Research|November 17, 2014
The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cellsYuan Gao, Fuju Wu, Jichun Zhou, et al.
The Journal of Clinical Investigation|October 3, 2022
TET3 epigenetically controls feeding and stress response behaviors via AGRP neuronsDi Xie, Bernardo Stutz, Feng Li, et al.
Pageof 22